How a MyCell®-Enhanced Formula Was Studied for Immune Support in Severe Illness - > READ ENTIRE STUDY
When researchers began searching for new ways to support the immune system during severe inflammatory challenges, one formulation stood out: ArtemiC, a blend containing MyCell®-enhanced curcumin, artemisinin, vitamin C, and boswellia.
A Phase II clinical trial explored how this combination behaved in patients hospitalized with COVID-19 — and the results offer fascinating insights into how advanced delivery systems may support the body during acute immune stress.
What the Study Was Designed to Explore
Researchers wanted to understand whether a blend of botanicals — each known for immune, anti-inflammatory, or antioxidant properties — could help patients recover more comfortably. The formulation used MyCell® technology to improve absorption and bioavailability.
The primary goals of the trial were to observe:
-
Changes in inflammatory markers
-
Recovery time
-
Ease of symptoms
-
Overall patient stability
This was not a drug trial — it was an observational study of how a natural ingredient blend functioned alongside standard supportive care.
Key Findings from the Clinical Trial
The study results highlighted several promising trends:
🔹 Reduced inflammatory markers
Patients taking ArtemiC showed reductions in several markers linked with inflammation and immune activation. This suggests a potential modulatory effect worth further study.
🔹 Improved symptom scores
Subjective symptoms improved more quickly in the ArtemiC group than in the control group.
🔹 Better overall clinical stability
Fewer patients in the treatment group required escalation of care.
While this trial focused specifically on hospitalized COVID-19 patients, the broader takeaway is clear:
When natural compounds are delivered in a highly bioavailable format, their physiological impact becomes more pronounced.
Why This Matters for the Future of Nutraceuticals
Many botanicals studied in integrative medicine — like curcumin, artemisinin, and boswellia — are notoriously difficult for the body to absorb. MyCell® technology improves their water solubility and bioavailability, which may enhance their physiological effects.
This study provides real-world evidence that:
better delivery systems can meaningfully influence outcomes in the context of immune challenges.
While Mitacell products are not ArtemiC and are not designed to treat disease, this research underscores why absorption matters — especially when the body is under stress.
Disclaimer:
This article summarizes published research on MyCell®-enhanced formulations. Mitacell products are not ArtemiC and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider for medical concerns.